NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call summary and Q&A section reveal strong financial performance, with 121% revenue growth and positive developments in consumer products. Strategic partnerships with major companies like AbbVie suggest future revenue potential despite delays. The company maintains guidance and expects cash flow positivity, indicating financial health. Although there are some uncertainties, like the AbbVie timeline and tariff impacts, the overall sentiment is positive, especially with strong sales from Silly George and new product launches. The positive sentiment outweighs the negatives, suggesting a likely positive stock price movement.

Key Financial Performance

Revenue $2.88 million, an increase of 100.3% year-over-year. The growth was driven by sales growth in both contract manufacturing and branded products.

Gross Margin 43.6%, more than double the 20.3% reported in Q2 2024. The increase was due to higher revenue from contract manufacturing and consumer branded products, including the acquisition of Silly George.

EBITDA Loss Negative $530,000, compared to negative $760,000 in Q2 2024. The narrowing loss was due to increased revenue and operational efficiencies.

Adjusted EBITDA Loss Negative $420,000, compared to negative $790,000 in Q2 2024. The improvement was attributed to higher revenue and better cost management.

Net Loss $670,000, compared to $890,000 in Q2 2024. The reduction in net loss was due to increased revenue and improved gross margins.

Contract Manufacturing Revenue $863,000, a 103% year-over-year increase from $425,000 in Q2 2024. The growth was driven by increased demand from existing customers and onboarding of new global corporations.

Consumer Products Revenue Increased 95% year-over-year, driven by growth across the entire brand portfolio, including new product launches and expanded offerings.

Cost of Revenues $1.63 million, up from $1.15 million in Q2 2024. The increase was aligned with sales of branded consumer products, particularly due to the acquisition of Silly George.

Selling, General and Administrative Expenses $1.89 million, up from $1.27 million in Q2 2024. The increase was due to higher compensation and benefits, share-based compensation, advertising, and professional fees.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Silly George product line expansion: Introduced 5 new shades of lip gloss, a hydrating lip mask, and under-eye patches crafted with proprietary hydrogel. Expected to contribute to Q3 and Q4 revenue.

Kenkoderm product line expansion: Doubling product portfolio to include eczema solutions, expanding from psoriasis care.

MEDAGEL product line expansion: Launched SilverSeal wound and burn kit and moist burn pads. Received Health Canada approval for SilverSeal sales in Canada.

STADA partnership expansion: Amended agreement to introduce new products targeting scars, stretch marks, and digestive enzyme formulas. $1 million non-dilutive funding provided for product launches and marketing.

Contract manufacturing growth: Revenue increased 103% YoY to $863,000, driven by new global corporations and existing customer demand. Partnerships include Cintas and iRhythm.

Consumer product revenue growth: Increased 95% YoY, driven by growth across brand portfolio and new product launches.

Revenue growth: Achieved $2.9 million in Q2 2025, a 100% YoY increase.

Gross margin improvement: Improved to 43.6% in Q2 2025 from 20.3% in Q2 2024.

EBITDA improvement: Adjusted EBITDA loss narrowed to $420,000 from $790,000 YoY.

STADA funding and collaboration: Received $1 million non-dilutive funding to support product launches and marketing.

Board of Directors expansion: Welcomed Steve Ciardiello, Chief Accounting Officer at Shutterstock, to the Board for strategic guidance.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Revenue dependency on partnerships: The company's revenue growth is significantly tied to partnerships with companies like Cintas, iRhythm, and STADA. Any disruption or termination of these partnerships could adversely impact revenue.

Supply chain risks: The company is expanding its product lines and entering new markets, which could strain its supply chain and logistics capabilities, potentially leading to delays or increased costs.

Regulatory hurdles: The company is awaiting FDA-related study results and has recently received Health Canada approval for a product. Regulatory delays or failures could hinder product launches and market entry.

Cash flow constraints: Despite recent funding, the company has a limited cash balance of $0.73 million as of June 30, 2025, which could pose challenges in sustaining operations and growth initiatives if additional funding is not secured.

Market competition: The company operates in highly competitive markets, including healthcare and consumer beauty products, which could pressure margins and limit market share growth.

Operational scaling challenges: The rapid growth in both contract manufacturing and branded products may lead to operational inefficiencies or quality control issues as the company scales.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Seasonal Revenue Expectations: The company anticipates a seasonally strong second half of 2025, with continued growth in revenue driven by both contract manufacturing and consumer branded products.

Contract Manufacturing Growth: The company expects contract manufacturing and white label to remain major drivers of expansion and success, supported by increased demand from existing customers and new agreements with global corporations.

Consumer Product Expansion: The company plans to launch new products in its Silly George, Kenkoderm, and MEDAGEL lines, including expanded beauty products, eczema solutions, and wound care kits. These launches are expected to contribute significantly to revenue in Q3 and Q4 2025.

Partnership with STADA: The company anticipates introducing additional products in collaboration with STADA as early as Q4 2025, with further launches planned for the first half of 2026. This includes digestive enzyme formulas and skin care solutions targeting scars and stretch marks.

Revenue and EBITDA Guidance: The company reaffirms its 2025 guidance of $13 million in revenue and achieving positive EBITDA during the year.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Could you talk about the market opportunities for the upcoming enzyme launches and how they compare to Histasolv?

A:Histasolv is a digestive enzyme targeting histamine sensitivity, a market affecting 2.5% to 3% of the population. It generates over $25 million annually in Europe. Upcoming enzymes, such as those targeting gluten, dairy, and fructose, as well as a vegan version of Histasolv, target much larger markets. The company aims to build a suite of solutions to enter the retail market.

Q:Do you have updates on when you could potentially enter the retail market? Are there thoughts about consolidating various brands under one brand for retail?

A:The company is in talks with large retailers, mostly for private label products like SilverSeal. Entering retail is 8-10 months away due to planogram timelines. Consolidating brands is not planned as they serve unique markets, though some products are combined under the MetaGel brand store.

Q:What is the current manufacturing capacity to supply more partners?

A:The plant utilization is in the high teens, much better than the 4% when the CEO started. There is significant capacity to produce more gel, and onboarding new customers is a 1.5- to 2-year process. The company expects to announce more customers as the year progresses.

Q:What is the revenue economic opportunity for the iRhythm partnership?

A:The company is under NDA and cannot disclose unit numbers. Most opportunities range between $300,000 to $1 million annually. Larger projects like AbbVie could generate millions in revenue, but they have faced delays.

Q:Has NEXGEL been impacted by tariffs either beneficially or negatively?

A:There is a mild negative impact on margins for some overseas products, but it has not been significant. On the positive side, there is increased interest in gels from domestic companies, which may translate into revenue in late Q3, Q4, and Q1 of next year.

Q:What is the status of the AbbVie partnership?

A:The AbbVie project has faced delays due to issues with another vendor. The timeline has shifted to the first quarter of 2026, with potential small orders before then. AbbVie has a $550 million financial commitment to the device, and the company remains optimistic.

Q:Can you tell us more about the new product from Silly George that started selling this quarter?

A:Silly George released variations of lashes, including a 75 Lash and Focus Packs, which have been popular. Sales of the 60 Pack are down 4%, but new packs added 17%-18% in sales with better margins. Upcoming products include lip gloss, lip and eye masks, and mascara.

Q:How are Silly George sales performing this quarter?

A:Sales are strong, with July being the biggest month of the year so far. The company hopes to maintain momentum into Q3 and Q4, especially with new product launches.

Q:What is the $1 million non-dilutive financing?

A:It is an advance against future profits with no recourse for repayment if unprofitable. The funds are used for launching 9 products, with repayment terms as low as 5% of profits and no interest.

Q:What is the current operating capacity for contract manufacturing and branded products?

A:The company operates well below 20% capacity in Langhorne and has ample room to expand in Texas. Capacity is not an issue, and plans are in place to scale if growth accelerates.

Q:How will the company handle a global recession or high interest rates?

A:The company focuses on high-margin consumer products, which are less impacted by tariffs. Advertising costs are the main expense. The company is prepared to adjust costs and margins if needed.

Q:Is the company targeting larger companies for contract manufacturing?

A:Yes, larger companies with robust medical device programs are the primary targets due to their stringent requirements, which align with the company's expertise.

Q:What is the status of NEXDrape and NEXDerm?

A:The company has pivoted to marketing adhesives for cataract surgical drapes to avoid 510(k) processes. NEXDerm remains a promising opportunity but is not a current focus due to resource allocation.

Q:What are the top partnerships for the company?

A:Key partnerships include Cintas, AbbVie, Owens & Minor, iRhythm, and STADA. STADA offers significant potential if initial products perform well. There are also unannounced opportunities in the pipeline.

Q:What percentage of the projected $13 million revenue will come from Silly George?

A:Approximately $6 to $6.5 million, nearly half of the projected revenue, will come from Silly George.

Q:Review of Unclear Management Responses

A:Management avoided providing specific revenue numbers for the iRhythm partnership due to an NDA. They also lacked clarity on the exact timeline for the AbbVie project, which has faced multiple delays. Additionally, the company did not provide detailed financial impacts of tariffs or specific plans for scaling capacity in the event of rapid growth.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

NXGL Transcript

NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript

Positive5-15

The earnings call highlighted a 25% YoY revenue increase, improved gross margins, and a shift from net loss to net income, indicating strong financial performance. Despite the lack of specific strategic guidance, the integration of the acquisition seems to be progressing well. The absence of risk discussion and unclear Q&A responses may slightly temper enthusiasm, but the overall financial health and operational efficiencies suggest a positive sentiment, likely leading to a 2% to 8% stock price increase.

NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript

Unknown11-11

The earnings call presents a mixed outlook. Financial performance is stable with improved margins and narrowed losses, but logistical delays and dependence on key partnerships pose risks. The Q&A reveals uncertainties, particularly with AbbVie and logistical challenges, dampening optimism. The reaffirmed guidance and potential positive EBITDA are countered by economic uncertainties and cash flow challenges. Without a clear market cap, the sentiment remains neutral, balancing positive operational efficiencies against logistical and partnership risks.

NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript

Positive8-12

NEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Call Transcript

Positive5-15

The earnings call indicates strong financial performance with a 121% revenue increase and improved margins. Despite ongoing challenges like supply chain issues and potential tariff impacts, the company shows resilience with strategic plans to mitigate risks. The Q&A reveals optimism about growth and product launches, though some uncertainties remain. The absence of a shareholder return plan is a minor drawback. Overall, the positive revenue growth, strategic partnerships, and improved financial health suggest a positive stock price movement in the short term.

NXGL Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.

Explore More Earnings

Get Started

NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript